Business
CervoMed to Present at the 8th International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic
About this update from Cervomed Inc.
BOSTON , Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam , on January 31, 2025 . The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here . Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) Format: Oral Presentation Presenter: John Alam , MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study Session Name : Symposium VIII-Therapy Session Date and Time: Friday, January 31, 2025 , 13:30pm CET / 7:30am ET The details of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation. About CervoMed CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant designed to inhibit p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in certain major neurological disorders. Investor Contact: PJ Kelleher LifeSci Advisors [email protected] 617-430-7579 Source: CervoMed Inc.